benserazide has been researched along with Debility in 1 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of our study was to assess the frailty phenotype prevalence in geriatric inpatients with mild parkinsonian signs (MPS) and to investigate levodopa test in the frail patients with MPS." | 1.46 | Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs. ( Bugdol, M; Czernek, M; Derejczyk, J; Kapko, W; Kawa, J; Marcisz, C; Seiffert, P; Stępień-Wyrobiec, O; Szymszal, J; Torbus, A, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seiffert, P | 1 |
| Derejczyk, J | 1 |
| Kawa, J | 1 |
| Marcisz, C | 1 |
| Czernek, M | 1 |
| Szymszal, J | 1 |
| Kapko, W | 1 |
| Bugdol, M | 1 |
| Torbus, A | 1 |
| Stępień-Wyrobiec, O | 1 |
1 other study available for benserazide and Debility
| Article | Year |
|---|---|
Frailty phenotype and the role of levodopa challenge test in geriatric inpatients with mild parkinsonian signs.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Benserazide; Case-Control Studies; Cross-Sectional Stud | 2017 |